[1] |
Galie N, Manes A, Palazzini M, et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger's syndrome[J]. Drugs, 2008, 68(8):1049-1066.
|
[2] |
Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease[J]. Circulation, 2007, 115(8):1039-1050.
|
[3] |
Duffels MG, Engelfriet PM, Berger RM, et al. Pulmonary arterial hypertension in congenital heart disease: an epidemiologic perspective from a Dutch registry[J]. Int J Cardiol, 2007, 120(2):198-204.
|
[4] |
中华医学会心血管病学分会肺血管病学组, 中华心血管病杂志编辑委员会. 中国肺高血压诊断和治疗指南2018[J]. 中华心血管病杂志, 2018, 46(12):933-964.
|
[5] |
中国医师学会心血管内科医师分会. 2015年先天性心脏病相关性肺动脉高压诊治中国专家共识[J]. 中国介入心脏病学杂志, 2015, 23(2):61-69.
|
[6] |
Baumgartner H, De Backer J, Babu-Narayan SV, et al. 2020 ESC Guidelines for the management of adult congenital heart disease[J]. Eur Heart J, 2021, 42(6):563-645.
|
[7] |
Dimopoulos K, Peset A, Gatzoulis MA. Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy[J]. Int J Cardiol, 2008, 129(2):163-171.
|
[8] |
中国医师学会心血管内科医师分会. 2015年先天性心脏病相关性肺动脉高压诊治中国专家共识[J]. 中国介入心脏病学杂志, 2015, 23(2):61-69.
|
[9] |
董琳, 何建国, 柳志红, 等. 成人肺动脉高压疾病特征的多中心临床研究[J]. 中华医学杂志, 2012, 92(16):1087-1090.
|
[10] |
O'Donnell C, Ruygrok PN, Whyte K, et al. Progressive pulmonary hypertension post atrial septal defect device closure-early symptomatic improvement may not predict outcome[J]. Heart Lung Circ, 2010, 19(12):713-716.
|
[11] |
D'Alto M, Romeo E, Argiento P, et al. Hemodynamics of patients developing pulmonary arterial hypertension after shunt closure[J]. Int J Cardiol, 2013, 168(4):3797-3801.
|
[12] |
张丹, 顾虹, 张陈, 等. 先天性心脏病术后合并肺动脉高压心导管检查及急性肺血管扩张试验分析[J]. 心肺血管病杂志, 2016, 35(5):369-372.
|
[13] |
中华医学会呼吸病学分会肺栓塞与肺血管病学组, 中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会, 全国肺栓塞与肺血管病防治协作组, 等. 中国肺动脉高压诊断与治疗指南(2021版)[J]. 中华医学杂志, 2021, 101(1):11-51.
|
[14] |
Dimopoulos K, Inuzuka R, Goletto S, et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension[J]. Circulation, 2010, 121(1):20-25.
|
[15] |
Takaya Y, Akagi T, Sakamoto I, et al. Efficacy of treat-and-repair strategy for atrial septal defect with pulmonary arterial hypertension[J]. Heart, 2022, 108(5):382-387.
|
[16] |
Xu J, Wang L, Shen Y, et al. Transcatheter closure for patent ductus arteriosus in patients with Eisenmenger syndrome: to do or not?[J]. BMC Cardiovasc Disord, 2020, 20(1):505.
|
[17] |
徐茁原, 李强强, 张陈, 等. 先天性心脏病相关肺动脉高压患者死亡的危险因素及不同亚型的临床特点[J]. 中华心血管病杂志, 2020, 48(4):315-322.
|
[18] |
Moceri P, Kempny A, Liodakis E, et al. Physiological differences between various types of Eisenmenger syndrome and relation to outcome[J]. Int J Cardiol, 2015, 179:455-460.
|
[19] |
He Y, Li Q, Zhang C, et al. Successful outcomes for atrial septal defect associated with pulmonary arterial hypertension using a "treat-repair-treat" strategy[J]. Int J Cardiol Congen Heart Dis, 2021, 2:100075.
|
[20] |
何缘, 李强强, 张陈, 等. 靶向药物联合缺损修复治疗成人先天性心脏病相关肺动脉高压的预后研究[J]. 心肺血管病杂志, 2021, 40(2):152-155,160.
|
[21] |
Bradley EA, Ammash N, Martinez SC, et al. "Treat-to-close": non-repairable ASD-PAH in the adult: Results from the North American ASD-PAH (NAAP) Multicenter Registry[J]. Int J Cardiol, 2019, 291:127-133.
|